{"filing":{"accession_number":"0001104659-26-097247","cik":"0001421642","ticker":"MSLE","company_name":"Satellos Bioscience Inc.","form":"6-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623194d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1421642/000110465926097247/tm2623194d1_6k.htm"},"events":[{"id":27974,"run_id":25551,"accession_number":"0001104659-26-097247","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is an at-the-market (ATM) sales agreement executed on August 14, 2026, authorizing Satellos Bioscience to issue and sell up to $50,000,000 of common shares through Leerink Partners LLC. The agreement explicitly permits sales \"at market prices prevailing at the time of sale\" and references an effective Registration Statement filed August 11, 2026. This is a dilutive equity issuance that would materially affect existing shareholders through potential share dilution and capital raising activity.","company_name":"Satellos Bioscience Inc.","ticker":"MSLE","filing_date":"2026-08-14","form":"6-K","submitted_at":null,"items":[{"id":29715,"accession_number":"0001104659-26-097247","item_number":"EX-99.1","item_title":"tm2623194d1_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is an at-the-market (ATM) sales agreement executed on August 14, 2026, authorizing Satellos Bioscience to issue and sell up to $50,000,000 of common shares through Leerink Partners LLC. The agreement explicitly permits sales \"at market prices prevailing at the time of sale\" and references an effective Registration Statement filed August 11, 2026. This is a dilutive equity issuance that would materially affect existing shareholders through potential share dilution and capital raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:43:13.043142+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29715,"accession_number":"0001104659-26-097247","item_number":"EX-99.1","item_title":"tm2623194d1_ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is an at-the-market (ATM) sales agreement executed on August 14, 2026, authorizing Satellos Bioscience to issue and sell up to $50,000,000 of common shares through Leerink Partners LLC. The agreement explicitly permits sales \"at market prices prevailing at the time of sale\" and references an effective Registration Statement filed August 11, 2026. This is a dilutive equity issuance that would materially affect existing shareholders through potential share dilution and capital raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:43:13.043142+00:00","company_name":"Satellos Bioscience Inc.","ticker":"MSLE","filing_date":"2026-08-14"}]}